← Back to Search

Ablation System

AcQBlate® Force Sensing Ablation System for Atrial Flutter (AcQForce AFL Trial)

N/A
Waitlist Available
Research Sponsored by Acutus Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 minutes post ablation
Awards & highlights

AcQForce AFL Trial Summary

This study is evaluating whether a new ablation device can safely and effectively treat atrial flutter.

Eligible Conditions
  • Atrial Flutter

AcQForce AFL Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 minutes post ablation
This trial's timeline: 3 weeks for screening, Varies for treatment, and 20 minutes post ablation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Subjects Achieving Acute Procedural Success
Subjects Free From Procedure/Device Related Serious Adverse Events (SAEs)

AcQForce AFL Trial Design

1Treatment groups
Experimental Treatment
Group I: Non-randomizedExperimental Treatment1 Intervention
All subjects with typical atrial flutter will undergo percutaneous catheter ablation of the cavotricuspid isthmus using the AcQBlate Force Sensing System.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AcQBlate® Force Sensing Ablation System
2021
N/A
~120

Find a Location

Who is running the clinical trial?

Acutus MedicalLead Sponsor
16 Previous Clinical Trials
1,835 Total Patients Enrolled
3 Trials studying Atrial Flutter
112 Patients Enrolled for Atrial Flutter

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~28 spots leftby Apr 2025